Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Rating of “Moderate Buy” by Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX) has been given an average rating of “Moderate Buy” by the eight brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $8.00.

Several analysts recently commented on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $4.00 target price on shares of Quince Therapeutics in a report on Thursday, November 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Quince Therapeutics in a report on Monday, November 24th. Zacks Research raised Quince Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. JMP Securities cut their target price on Quince Therapeutics from $9.00 to $8.00 and set a “market outperform” rating for the company in a research report on Tuesday, August 12th. Finally, Citigroup started coverage on Quince Therapeutics in a research report on Tuesday, August 5th. They issued an “outperform” rating on the stock.

Hedge Funds Weigh In On Quince Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd acquired a new stake in shares of Quince Therapeutics during the 2nd quarter worth approximately $37,000. Virtu Financial LLC lifted its stake in Quince Therapeutics by 48.4% during the first quarter. Virtu Financial LLC now owns 43,332 shares of the company’s stock worth $58,000 after purchasing an additional 14,128 shares during the last quarter. GSA Capital Partners LLP lifted its stake in Quince Therapeutics by 158.0% during the third quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock worth $142,000 after purchasing an additional 53,417 shares during the last quarter. Bridgeway Capital Management LLC boosted its holdings in shares of Quince Therapeutics by 20.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after purchasing an additional 22,200 shares in the last quarter. Finally, Rockefeller Capital Management L.P. bought a new position in shares of Quince Therapeutics in the 2nd quarter valued at $280,000. 30.75% of the stock is currently owned by institutional investors and hedge funds.

Quince Therapeutics Trading Up 5.7%

QNCX opened at $3.65 on Friday. The stock’s fifty day simple moving average is $1.90 and its 200 day simple moving average is $1.64. Quince Therapeutics has a 1-year low of $0.72 and a 1-year high of $3.73. The stock has a market cap of $202.95 million, a PE ratio of -3.01 and a beta of 1.07.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). Equities analysts forecast that Quince Therapeutics will post -1.21 earnings per share for the current year.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.